Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · IEX Real-Time Price · USD
11.05
+0.55 (5.24%)
At close: Mar 27, 2024, 4:00 PM
10.97
-0.08 (-0.72%)
Pre-market: Mar 28, 2024, 4:26 AM EDT
Phathom Pharmaceuticals Market Cap
Phathom Pharmaceuticals has a market cap or net worth of $608.75 million as of March 28, 2024. Its market cap has increased by 125.55% in one year.
Market Cap
608.75M
Enterprise Value
663.34M
1-Year Change
125.55%
Ranking
Category
Stock Price
$11.05
Market Cap Chart
Since October 25, 2019, Phathom Pharmaceuticals's market cap has decreased from $636.70M to $608.75M, a decrease of -4.39%. That is a compound annual growth rate of -1.01%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 26, 2024 | 614.00M | 0.47% |
Mar 25, 2024 | 611.10M | -5.17% |
Mar 22, 2024 | 644.40M | 20.29% |
Mar 21, 2024 | 535.70M | 0.45% |
Mar 20, 2024 | 533.30M | 5.79% |
Mar 19, 2024 | 504.10M | 4.11% |
Mar 18, 2024 | 484.20M | -2.48% |
Mar 15, 2024 | 496.50M | 9.26% |
Mar 14, 2024 | 454.40M | -2.86% |
Mar 13, 2024 | 467.80M | -2.09% |
Mar 12, 2024 | 477.80M | -1.08% |
Mar 11, 2024 | 483.00M | -6.99% |
Mar 8, 2024 | 519.30M | -2.31% |
Mar 7, 2024 | 531.60M | -4.58% |
Mar 6, 2024 | 557.10M | -2.01% |
Mar 5, 2024 | 568.50M | -3.50% |
Mar 4, 2024 | 589.10M | -3.74% |
Mar 1, 2024 | 612.00M | -0.10% |
Feb 29, 2024 | 612.60M | -0.75% |
Feb 28, 2024 | 617.20M | 6.21% |
Feb 27, 2024 | 581.10M | 2.41% |
Feb 26, 2024 | 567.40M | -6.51% |
Feb 23, 2024 | 606.90M | 1.25% |
Feb 22, 2024 | 599.40M | 2.55% |
Feb 21, 2024 | 584.50M | 0.38% |
View and export this data all the way back to 2019.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Novavax | 673.17M |
Nurix Therapeutics | 666.92M |
OPKO Health | 666.12M |
Savara | 665.87M |
Fulgent Genetics | 659.44M |
Acelyrin | 656.07M |
Tevogen Bio Holdings | 653.52M |
Mineralys Therapeutics | 641.24M |